Recognizing that the US FDA recently approved the plant cell-based oral delivery of biologics to induce tolerance against peanut allergies, the required regulatory pathways are in place to exploit the reduced costs and favorable implementation attributes of orally available, plant-derived therapeutics for delivering ACE2/Ang(1–7). The gene discussed is ACE2; the disease is peanut allergic reaction.